Skip to main content

Table 2 Cost associated with the societal perspective (median, IQR), in 2022 US dollars

From: Estimating the economic burden of respiratory syncytial virus infections in infants in Vietnam: a cohort study

Cost components

Outpatient

Inpatient at RD

ICU***

All

(N = 210)

RSV positive

(n = 21)

RSV negative

(n = 189)

p-value**

All inpatients

(N = 318)

RSV positive

(n = 84)

RSV Negative

(n = 234)

p-value**

All RSV negative

(n = 8)

Total costs

52 (32–86)

52 (32–85)

52 (3

2–86)

0.71

184 (110–287)

165 (95–249)

190 (123–292)

0.04

2146 (1038–4067)

Direct medical costs

22

(13–32)

26 (16–32)

21 (13–32)

0.35

84 (50–135)

68 (47–102)

91 (59–153)

0.001

1996 (937–3786)

 Consultation fee

3 (2–4)

2 (2–3)

3 (2–4)

0.20

3 (2–6)

3 (2–6)

3 (2–5)

0.67

4 (2–6)

 Medication costs

15 (9–20)

15 (8–18)

15 (9–20)

0.46

9 (4–19)

10 (4–21)

9 (5–19)

0.85

114 (20–678)

 Laboratory costs

0 (0–2)

0 (0–2)

0 (0–2)

0.88

2 (2–13)

2 (0–3)

4 (2–17)

< 0.001

193 (64–359)

 Procedure & service cost

6 (3–11)

8 (4–13)

6 (3–11)

0.14

49 (24–71)

29 (19–58)

50 (29–88)

< 0.001

1356 (524–2468)

 Imaging costs

3 (3–5)

3 (3–3)

3 (3–5)

0.85

6 (3–16)

3 (3–12)

6 (3–16)

0.03

28 (10–85)

 Miscellaneous costs*

8 (1–13)

0 (0–0)

8 (1–13)

N/A

13 (6–23)

12 (6–23)

13 (6–23)

0.31

204 (120–332)

Direct non-medical costs

5 (2–28)

4 (2–22)

5 (2–28)

0.82

35 (3–87)

27

(3–72)

38 (3–88)

0.57

76 (42–112)

 Transport costs

4 (2–27)

4 (2–22)

4 (2–27)

0.91

6 (2–28)

8 (2–41)

5 (1–24)

0.12

33 (3–78)

 Meal costs

0 (00)

0 (0–0)

0 (0–0)

0.18

32 (0–63)

2 (0–39)

41 (0–70)

0.001

5 (2–52)

 Accommodation costs

0 (0–0)

0 (0–0)

0 (0–0)

N/A

0 (0–30)

0 (0–0)

16 (0–32)

< 0.001

10 (0–233)

 Caretaker costs

0 (0–0)

0 (0–0)

0 (0–0)

N/A

6 (0–38)

47 (34–60)

0 (0–13)

0.07

0 (0–0)

Indirect costs

11 (2–26)

22 (9–34)

9 (0–25)

0.09

19 (0–69)

18 (0–69)

20 (0–69)

0.93

85 (6–253)

 Lost income

9 (0–25)

17 (9–34)

8 (0–22)

0.03

17 (0–69)

12 (0–68)

17 (0–69)

0.85

13 (4–194)

 Lost leisure

6 (2–6)

3 (0–6)

6 (2–6)

0.18

2 (1–6)

6 (2–9)

2 (1–5)

0.05

3 (2–5)

Prior to hospital costs

11 (1–26)

5 (1–22)

11 (1–26)

0.43

17 (9–35)

17 (9–37)

18 (9–35)

0.82

45 (25–93)

In-hospital costs

29 (17–49)

27 (11–35)

30 (17–49)

0.32

161 (94–268)

137 (72–214)

181 (103–282)

0.005

1660 (861–4010)

Follow-up visit costs

18 (7–33)

26 (16–49)

17 (7–32)

0.05

0 (0–9)

0 (0–6)

2 (0–11)

0.005

13 (2–227)

  1. *Miscellaneous costs include medical consumables such as syringes, gloves, and soap
  2. **Mann–Whitney U p-value comparing between the costs associated with RSV and those associated with no RSV
  3. ***No ICU cases were identified as RSV positive
  4. ICU: intensive care unit; IQR: interquartile range; RD: Respiratory Department; RSV: respiratory syncytial virus, N/A: not applicable